Global Mammography Horizon: Market Structure, Forecasts, Competitive Dynamics, and AI Monetization Architecture, 2024A-2035F

This report provides a strategic assessment of the global mammography market and the broader breast imaging ecosystem from 2024A through 2035F. Coverage includes full-field digital mammography (FFDM), digital breast tomosynthesis (DBT), contrast-enhanced mammography (CEM), mammography-specific software and workstations, breast AI, density and risk tools, service and aftermarket, mobile mammography, image-guided breast intervention, and breast ultrasound and breast MRI adjacencies.

Mammography remains one of the most established screening infrastructure markets in medical imaging, yet competitive and commercial value is shifting beyond the gantry. Dedicated systems, DBT, CEM-capable gantries, service contracts, workflow software, AI, breast biopsy, mobile screening and supplemental imaging are increasingly connected through the same commercial decision chain.

Developed through Markintel®, the analyst's proprietary research methodology and strategic framework system, the report is designed for imaging OEMs, AI and workflow vendors, investors, corporate development teams, strategy and commercial leaders, healthcare providers, distributors and component suppliers.

Key Questions Answered

• Where does mammography still grow when gantry hardware is mature?
• Which value pools sit inside the Core Mammography Market, and which sit in adjacent breast imaging pathways?
• How should vendors approach AI monetization when provider-gross value can be larger than vendor-booked software revenue?
• Where is CEM most commercially relevant?
• Which companies control the installed base, service, biopsy pathway, enterprise workflow, AI layer, provider volume, and China and value-tier channels?
• How do regional strategies differ across the U.S., Europe, China, Japan, India, Latin America, and the Middle East and Africa?

Market Snapshot

The global mammography market is structurally mature but strategically active. The gantry pool remains the anchor, while the most important growth and competitive movement occurs around it: AI and workflow software, CEM-enabled diagnostic pathways, service retention, interventional breast procedures, breast ultrasound, breast MRI, mobile access infrastructure and risk-based screening.

The report separates three layers so readers can evaluate size and growth without blending distinct revenue pools: the Core Mammography Market (dedicated systems, mammography-specific service, software and workstations, and AI and workflow); the Interventional Breast Pathway (biopsy systems, localization and image-guided intervention); and the Breast Imaging Ecosystem Opportunity, which adds breast ultrasound and breast MRI adjacencies. A flat or modestly growing gantry market can still control a larger and faster-moving ecosystem.

Key Market Trends

1. Advantage is migrating beyond gantry specifications. Control of the installed base, service, AI, CEM, biopsy, enterprise workflow, provider economics and patient access increasingly decides competitive position.
2. AI monetization needs a provider-value bridge. Breast AI can create provider-gross value well above the software revenue a vendor books, which changes how products should be priced and packaged.
3. CEM adds a premium diagnostic pathway. CEM-enabled workups and premium overlay strategy raise the value of the installed gantry base.
4. Replacement cycles and screening policy anchor demand. Installed-base replacement, screening-program participation and system utilization set equipment demand, while DBT maturity shapes the premium mix.
5. Value-tier and China channels pressure pricing. Public procurement, tenders and value-tier competition, including China's two-channel structure, weigh on equipment ASPs.
6. Access infrastructure widens the market. Mobile mammography, telemammography and risk-based screening support growth in access-expansion markets.

Competitive Structure

The report analyzes competitive dynamics across systems OEMs, China and value-tier suppliers, breast AI and density and risk vendors, enterprise imaging and workflow platforms, biopsy and interventional companies, provider networks and mobile access operators, and detector, CEM and contrast suppliers, using a competitive control-plane analysis.

Companies covered include Hologic, GE HealthCare, Siemens Healthineers, Fujifilm, Canon Medical, Planmed, IMS Giotto, United Imaging, Wandong, Mindray, ScreenPoint Medical, Lunit, Volpara, DeepHealth, iCAD, Vara, Therapixel, Visage Imaging / Pro Medicus, Sectra, Intelerad, Mammotome, BD, Merit Medical, RadNet, Solis Mammography, SimonMed Imaging, Redlen Technologies, Varex Imaging, Bayer, Bracco and Guerbet.

What's Inside

Core model, 2024A-2035F: Procedure volume, installed base, annual shipments, equipment and gantry revenue, service contracts, mammography-specific software and workstations, and AI and workflow software, rolling up to the Core Mammography Market, the Interventional Breast Pathway, breast ultrasound and breast MRI adjacencies, and the Breast Imaging Ecosystem Opportunity.

Technology and workflow coverage: 2D FFDM, DBT, CEM, AI detection and second-reader workflows, density and risk AI, enterprise breast workflow and viewers, mobile mammography and telemammography, and biopsy workflow. Photon-counting mammography is treated as a scenario and watchlist technology.

Market-structure views: Replacement-cycle dynamics, screening-policy and utilization context, procurement and tender evidence, service and installed-base economics, CEM and premium overlay strategy, and the AI monetization and provider-gross value bridge.

Markintel® strategic frameworks: M³ Market Momentum Matrix, M-TEM, T-DIC, Solution Adoption & Growth Matrix, ARC-Index, Ecosystem Collaboration Matrix and Upgrade & Package Ladder.

Regional and country analysis: North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa, with country analysis of the United States, Canada, Germany, France, the United Kingdom, Italy, China, Japan, India, South Korea, Australia, Brazil, Mexico and South Africa, plus named regional clusters.

Who Should Read This Report

• Imaging OEM executives and product leaders
• Breast AI and workflow software vendors
• Biopsy and interventional breast companies
• Healthcare providers, screening networks and distributors
• Strategy, commercial and corporate development leaders
• Investors and component suppliers

Why This Report

By separating the Core Mammography Market, the Interventional Breast Pathway and the broader ecosystem, the report lets readers size opportunities without blending distinct revenue pools. Its regional model distinguishes mature replacement markets, access-expansion markets, screening-program markets, premium private-network markets, public and value procurement markets, and China's two-channel structure, so strategy can be matched to how each market actually buys.